HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired lipodystrophy in patients on highly active antiretroviral therapy?

HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired lipodystrophy in patients on highly active antiretroviral therapy?

HIV-PIs (HIV protease inhibitors) have proved to be of great benefit for the millions of people suffering from AIDS. However, one of the side effects of this component of combined highly active antiretroviral therapy is lipodystrophy, which affects a large number of the patients taking this class of...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Goulbourne, C, Vaux, D
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Portland Press 2010

Παρόμοια τεκμήρια

The structural basis of ZMPSTE24-dependent laminopathies
ανά: Quigley, A, κ.ά.
Έκδοση: (2013)

The structural basis of ZMPSTE24-dependent laminopathies.
ανά: Quigley, A, κ.ά.
Έκδοση: (2013)

Prelamin A and ZMPSTE24 in premature and physiological aging
ανά: Howard J. Worman, κ.ά.
Έκδοση: (2023-12-01)

ZMPSTE24 Is Associated with Elevated Inflammation and Progerin mRNA
ανά: Moritz Messner, κ.ά.
Έκδοση: (2020-08-01)

Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24.
ανά: Jemima Barrowman, κ.ά.
Έκδοση: (2012-01-01)

Acquired and Inherited Lipodystrophies
Έκδοση: (2004-06-01)

Lipodystrophy in HIV/AIDS patients with different levels of physical activity while on antiretroviral therapy
ανά: Aline Francielle Mota Segatto, κ.ά.
Έκδοση: (2011-08-01)

Lipodystrophy in Human Immunodeficiency Virus (HIV) Patients on Highly Active Antiretroviral Therapy (Haart)
ανά: N. Sunil Kumar, κ.ά.
Έκδοση: (2015-07-01)

Inhibition of Arenavirus Entry and Replication by the Cell-Intrinsic Restriction Factor ZMPSTE24 Is Enhanced by IFITM Antiviral Activity
ανά: Robert J. Stott-Marshall, κ.ά.
Έκδοση: (2022-02-01)

运用二代测序技术产前诊断ZMPSTE24基因突变
ανά: 麦明琴, κ.ά.
Έκδοση: (2017-01-01)

The Senolytic Drug Fisetin Attenuates Bone Degeneration in the Zmpste24−/− Progeria Mouse Model
ανά: William S. Hambright, κ.ά.
Έκδοση: (2023-01-01)

Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
ανά: Ayako Nagayama, κ.ά.
Έκδοση: (2021-05-01)

Targeting CK2 eliminates senescent cells and prolongs lifespan in Zmpste24-deficient mice
ανά: Jie Zhang, κ.ά.
Έκδοση: (2024-05-01)

HIV-1 protease as a target for antiretroviral therapy
ανά: Windsor, Ian William.
Έκδοση: (2019)

Acquired lipodystrophy following use of pembrolizumab
ανά: Maya Weitzen, κ.ά.
Έκδοση: (2024-12-01)

Acquired partial lipodystrophy associated with varicella
ανά: Zafer Kurugöl, κ.ά.
Έκδοση: (2009-12-01)

The Lipodystrophy Syndrome in HIV-Infected Children under Antiretroviral Therapy: A First Report from the Central Africa
ανά: Honoré Kalombayi Tshamala, κ.ά.
Έκδοση: (2019-01-01)

Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome.
ανά: Pere Domingo, κ.ά.
Έκδοση: (2010-11-01)

Influence of the duration of antiretroviral use on insulin resistance among people living with HIV with lipodystrophy
ανά: Thiago Rodrigues Faria Vitorazzi, κ.ά.
Έκδοση: (2018-12-01)

Defining substrate requirements for cleavage of farnesylated prelamin A by the integral membrane zinc metalloprotease ZMPSTE24.
ανά: Kaitlin M Wood, κ.ά.
Έκδοση: (2020-01-01)

The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B
ανά: Kamsi O. Odinammadu, κ.ά.
Έκδοση: (2023-12-01)

Lipodystrophy syndrome in HIV /
ανά: Wanke, Christine A., κ.ά.
Έκδοση: (2003)

The Place of protease inhibitors in antiretroviral treatment
ανά: S.B. Tenore, κ.ά.

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
ανά: Bwakura-Dangarembizi, M, κ.ά.
Έκδοση: (2015)

Mass spectrometry captures off-target drug binding and provides mechanistic insights into the human metalloprotease ZMPSTE24
ανά: Mehmood, S, κ.ά.
Έκδοση: (2016)

ZMPSTE24 missense mutations that cause progeroid diseases decrease prelamin A cleavage activity and/or protein stability
ανά: Spear, ED, κ.ά.
Έκδοση: (2018)

Accelerated aging in articular cartilage by ZMPSTE24 deficiency leads to osteoarthritis with impaired metabolic signaling and epigenetic regulation
ανά: Jinlong Suo, κ.ά.
Έκδοση: (2023-05-01)

A Heterozygous ZMPSTE24 Mutation Associated with Severe Metabolic Syndrome, Ectopic Fat Accumulation, and Dilated Cardiomyopathy
ανά: Damien Galant, κ.ά.
Έκδοση: (2016-04-01)

ZMPSTE24 missense mutations that cause progeroid diseases decrease prelamin A cleavage activity and/or protein stability
ανά: Eric D. Spear, κ.ά.
Έκδοση: (2018-07-01)

Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch
ανά: Simeon Eche, κ.ά.
Έκδοση: (2021-03-01)

Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.
ανά: Cordula Frohoff, κ.ά.
Έκδοση: (2011-02-01)

Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
ανά: Musiime, V, κ.ά.
Έκδοση: (2014)

Barraquer–Simons Lipodystrophy Syndrome in an Otherwise Normal Child: A Rare Case of Acquired Partial Lipodystrophy
ανά: Kananbala Sahu, κ.ά.
Έκδοση: (2021-01-01)

A rare phenomenon of atypical lipodystrophy in a patient on HAART in the absence of a protease inhibitor regimen
ανά: Mohammed Mitha, κ.ά.
Έκδοση: (2010-11-01)

Overview of HIV-related lipodystrophy
ανά: T Marie Rossouw, κ.ά.
Έκδοση: (2013-02-01)

Hiv-associated lipodystrophy and exercise
ανά: E. Mutimura, κ.ά.
Έκδοση: (2006-02-01)

Restrictive Dermopathy Due to ZMPSTE24 Mutation: A Case Report with a Novel Finding of Corpus Callosum Agenesis
ανά: Minu Jose Chiramel, κ.ά.
Έκδοση: (2024-01-01)

Deficiency in ZMPSTE24 and resulting farnesyl–prelamin A accumulation only modestly affect mouse adipose tissue stores[S]
ανά: Patrick J. Heizer, κ.ά.
Έκδοση: (2020-03-01)

Inherited and acquired lipodystrophies: molecular-genetic and autoimmune mechanisms
ανά: Ekaterina L. Sorkina, κ.ά.
Έκδοση: (2018-04-01)

Acquired partial lipodystrophy: An atypical presentation with therapeutic challenge
ανά: Komali Garlapati, κ.ά.
Έκδοση: (2015-01-01)